Effectiveness of chemotherapy after anti‐PD‐1 blockade failure for relapsed and refractory Hodgkin lymphoma-Reference-Cited by-同舟云学术

Effectiveness of chemotherapy after anti‐PD‐1 blockade failure for relapsed and refractory Hodgkin lymphoma

Published:2020-09-02 Issue:21 Volume:9 Page:7830-7836
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Casadei Beatrice¹,Argnani Lisa¹,Morigi Alice¹,Lolli Ginevra¹,Broccoli Alessandro¹,Pellegrini Cinzia¹,Nanni Laura¹,Stefoni Vittorio¹,Coppola Paolo E.¹,Carella Matteo¹,Cavo Michele¹,Zinzani Pier Luigi¹^ORCID

Affiliation:

1. Institute of Hematology “L. e A. Seràgnoli” University of Bologna Bologna Italy

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3262

Reference24 articles.

1. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

2. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

3. Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma

4. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

5. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice;Cancers;2024-05-10

2. Successful treatment of paediatric refractory Hodgkin lymphoma with immunotherapy – A case report and literature review;Acta Paediatrica;2024-04-10

3. Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial;BMC Medicine;2024-03-07

4. Front-line Chemo-immunotherapy with Nivolumab and Dose-Adjusted EPOCH in Peripheral T-cell Lymphoma: A Phase I Trial;Blood Advances;2023-12-27

5. Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma;British Journal of Haematology;2023-10-31